Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
GeriPal
DECEMBER 15, 2022
Summary Transcript Summary. We’ve talked at length on prior podcasts about the failures of aducnumab, Biogen, and the FDA’s decision to approve it. . But wait, there’s a shiny new anti-amyloid drug, lecanemab! (No No it’s not just the French version of Aducanumab). . In an article in the NEJM (a published article this time, wonder of wonders!)
105 
Let's personalize your content